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Fibroblast Growth Factor 19
Increases the Excitability of
Pre-Motor Glutamatergic Dorsal
Vagal Complex Neurons From
Hyperglycemic Mice
Jordan B. Wean1 and Bret N. Smith1,2*
1 Department of Physiology, College of Medicine, University of Kentucky, Lexington, KY, United States, 2 Department of
Neuroscience, College of Medicine, University of Kentucky, Lexington, KY, United States
Intracerebroventricular administration of the protein hormone fibroblast growth factor 19
(FGF19) to the hindbrain produces potent antidiabetic effects in hyperglycemic mice that
are likely mediated through a vagal parasympathetic mechanism. FGF19 increases the
synaptic excitability of parasympathetic motor neurons in the dorsal motor nucleus of the
vagus (DMV) from hyperglycemic, but not normoglycemic, mice but the source of this
synaptic input is unknown. Neurons in the area postrema (AP) and nucleus tractus
solitarius (NTS) express high levels of FGF receptors and exert glutamatergic control over
the DMV. This study tested the hypothesis that FGF19 increases glutamate release in the
DMV by increasing the activity of glutamatergic AP and NTS neurons in hyperglycemic
mice. Glutamate photoactivation experiments confirmed that FGF19 increases synaptic
glutamate release from AP and NTS neurons that connect to the DMV in hyperglycemic,
but not normoglycemic mice. Contrary to expectations, FGF19 produced a mixed effect
on intrinsic membrane properties in the NTS with a trend towards inhibition, suggesting
that another mechanism was responsible for the observed effects on glutamate release in
the DMV. Consistent with the hypothesis, FGF19 increased action potential-dependent
glutamate release in the NTS in hyperglycemic mice only. Finally, glutamate
photoactivation experiments confirmed that FGF19 increases the activity of
glutamatergic AP neurons that project to the NTS in hyperglycemic mice. Together,
these results support the hypothesis that FGF19 increases glutamate release from AP and
NTS neurons that project to the DMV in hyperglycemic mice. FGF19 therefore modifies the
local vago-vagal reflex circuitry at several points. Additionally, since the AP and NTS
communicate with several other metabolic regulatory nuclei in the brain, FGF19 in the
hindbrain may alter neuroendocrine and behavioral aspects of metabolism, in addition to
changes in parasympathetic output.
Keywords: diabetes, fibroblast growth factor, hyperglycemia, vagus nerve, EPSC, area postrema, nucleus tractus
solitarius, parasympathetic
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INTRODUCTION
Fibroblast growth factor 19 (FGF19) is an ileal-derived protein
hormone that produces potent, anti-diabetic, and anti-obesogenic
effects. Although early work suggested that these effects were
mediated mainly by FGF19 acting on peripheral targets, several
reports have now found that acute intracerebroventricular (ICV)
administration of FGF19 may act at multiple distinct sites in the
brain to regulate energy balance. Lateral ventricle administration of
FGF19 increases metabolic rate (1), while 3rd ventricular
administration was found to decrease food intake, lower insulin
resistance, improve glucose tolerance, and reduce blood glucose
concentrations in rodent models of diabetes and obesity (2–5).
These findings suggest a hypothalamic mechanism since FGF19 was
found to suppress AGRP/NPY activity (4) and decrease plasma
ACTH (2). However, we demonstrated that 4th ventricular
administration of FGF19 also decreases blood glucose in type 1
diabetic (T1DM) mice, suggesting the hindbrain as an
underappreciated target tissue for this system (6).
The brainstem dorsal vagal complex (DVC) is an important
homeostatic regulatory center that tightly controls parasympathetic
output in response to numerous convergent inputs, both neuronal
and humoral. The DVC is principally comprised of the area
postrema (AP), the nucleus tractus solitarius (NTS), and the
dorsal motor nucleus of the vagus (DMV). The NTS integrates
vagal afferent, viscerosensory information with input from several
brain areas, including the hypothalamus and AP (7–10). In turn, the
NTS regulates neural activity in the DMV through both
glutamatergic and GABAergic projections (11, 12). Finally, DMV
neurons project cholinergic outputs through the efferent vagus
nerve to regulate hepatic glucose production, gastric motility, and
pancreatic exocrine secretion, among other visceral regulatory
functions (13–18). Additionally, the AP and NTS contain
fenestrated capillaries that permit the passage of humoral
components that may be excluded by the blood-brain barrier
elsewhere (19, 20). DVC neurons respond to many primary
metabolic hormones including insulin, leptin, ghrelin, glucagon,
GLP-1 (21–25) and importantly, FGF19 (6). The DVC, especially
the AP and NTS, contains multiple FGF receptors (FGFR) as well as
ß-klotho, an obligate co-receptor (26–28), suggesting that neuronal
activity in the DVC may regulate metabolic homeostatic
mechanisms in response to endogenous FGF signaling.
In a mouse model of type 1 diabetes (T1DM), FGF19
consistently and robustly increased action potential-dependent
excitatory synaptic transmission to the DMV (6). This suggests
that FGF19 increases the activity of glutamatergic neurons
immediately afferent to the DMV, which remain intact in the
slice preparation. A likely source of these glutamatergic inputs is
the NTS since the NTS to DMV connection is well documented
(12, 29–31) and is open to modulation by various other
peptides and neurotransmitters (31–34). Interestingly, receptor
expression data suggest that the AP could also be a target for
FGF19 since the AP expresses significantly more FGFR than
surrounding areas (28) and expresses more ß-klotho and FGFR2
than any other brain area, in addition to high levels of FGFR1
and FGFR3 (26). Moreover, glutamatergic AP neurons project
extensively to the NTS and DMV (35). Taken together, these
findings suggest that FGF19 may act on intrinsic DVC circuitry
to modify synaptic input to the DMV and consequently
modulate vagally-mediated glucoregulation.
This study tests the hypothesis that FGF19 increases excitatory
neurotransmission in the DVC by altering excitability of NTS and
AP neurons. In addition to functioning within local DVC circuits,
the NTS and AP communicate bidirectionally with other brain areas
thought to be involved in regulating energy metabolism (7, 8, 36).
Thus, FGF19-mediated alteration of neuronal activity in these areas
is likely to have wide-reaching metabolic effects by modulating
vago-vagal circuit dynamics as well as influencing more distal areas
that control ingestive behaviors and regulate energy balance through
autonomic or neuroendocrine means.
MATERIALS AND METHODS
Animals
All mice used for experiments were juvenile (3-8 weeks old) male
and female FVB mice (FVB-Tg(GadGFP)4570Swn/J, FVB;
Jackson Laboratory, Bar Harbor, ME, USA). This mouse
expresses enhanced green fluorescent under the control of the
GAD67 promoter and allows for the visual identification of
GABAergic neurons. Animals were housed under 14:10 light-
dark conditions in the University of Kentucky Division of
Laboratory Animal Resources facilities with food and water
available ad-libitum. Approximately equal numbers of both
sexes were used and results from both sexes were aggregated.
All animal procedures were approved by the University of
Kentucky Animal Care and Use Committee.
To destroy insulin-secreting pancreatic b-cells, mice were
given an intraperitoneal injection of streptozotocin (STZ; 200
mg/kg in 0.15mL of 0.1 M citric acid; Sigma-Aldrich, St. Louis,
MO, USA) after a 6-hour fast. After injection, mice were
returned to their home cages and blood glucose was monitored
daily by tail lance (Nova Max Plus, Nova Diabetes Care, Billerica,
MA, USA). Mice were used for experiments after ≥5 days of
continual hyperglycemia (≥ 300 mg/dL). It has been previously
established that a similar period of hyperglycemia is sufficient to
produce lasting changes in both synaptic and intrinsic properties
of NTS and DMV neurons (37–42). Mice that displayed
persistent hyperglycemia after STZ injection were considered a
model of T1DM.
Electrophysiology
Mice were anesthetized using isoflurane inhalation (confirmed
using foot pinch response) and decapitated at between 1000
and 1200 hrs. The brain was then rapidly removed and placed
in ice-cold, oxygenated (2-4°C; 95% O2/5% CO2) artificial
cerebrospinal fluid (ACSF). In all experiments (except where
the addition of drugs is noted), ACSF was composed of (in mM):
124 NaCl, 3 KCl, 26 NaHCO3, 1.4 NaH2PO4, 11 glucose, 1.3
CaCl2, and 1.3 MgCl2. The hindbrain was mounted to a
sectioning stage using cyanoacrylate glue and submerged in
ACSF. Coronal brainstem slices (300 µm) were made using a
vibratome (Series 1000; Technical Products International, St.
Louis, MO, USA). After cutting, slices were incubated in a
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holding chamber for 1 hour in warmed (30°C-35°C),
oxygenated ACSF.
For recordings, slices were transferred to a recording chamber on
a fixed-stage, upright microscope (BX51WI; Olympus, Melville, NY,
USA) and superfused with warmed ACSF (32-34°C). Whole-cell
patch-clamp recordings were performed under visual control and
cells were identified using infrared illumination with differential
interference contract optics. Glass recording pipettes (1.65 mmOD,
1.2 mm ID; King Precision Glass, Claremont, CA, USA) were filled
with internal solution that contained (in mM): 130 K-gluconate, 1
NaCl, 5 EGTA, 10 HEPES, 1 MgCl2, 1 CaCl2, 3 KOH, and 2 Mg-
ATP; pH = 7.2-7.3, adjusted with 5M KOH. Recordings were made
using a Multiclamp 700B amplifier, Digidata 1440A digitizer, and
pClamp 10.6 software (Molecular Devices, Axon Instruments,
Sunnyvale, CA, USA). Data were recorded at 20 kHz and filtered
at 3 kHz.
Added to the ACSF for specific experiments were the
following: Fibroblast growth factor 19 (FGF19; 230 pM;
ProspecBio, Ness Ziona, Israel), 4-Methoxy-7-nitroindolinyl-
caged-L-glutamate (MNI caged glutamate; 250 µM; Tocris/
BioTechne, Minneapolis, MN, USA), tetrodotoxin (TTX; 2mM;
Alomone Labs, Jerusalem, Israel), and picrotoxin (100 mM;
Alomone Labs). The concentration for FGF19 was chosen
because we have previously shown that this concentration
alters intrinsic and synaptic properties of DMV neurons (6).
Additionally, this concentration has been shown to stimulate
approximately half-maximal glucose uptake and phosphorylated
extracellular signal-related kinase (pERK) induction in cell
culture assays (43). FGF19 was applied for 5 minutes and was
applied once per slice to avoid any lasting effects of
prior applications.
DMV neurons were identified by morphology (elongated,
tear-drop-shaped soma ≥ 20 µm) and by their location in the
slice (located along the ventral edge of the DVC). NTS neurons
were also identified by morphology and location in slice (dorsal
to the DMV). The mouse model used here expresses enhanced
green fluorescent protein (EGFP) under a GAD67 promoter.
This allows for visual identification of a large proportion of
GABAergic NTS neurons. Since previous research suggested that
FGF19 altered glutamatergic, but not GABAergic transmission in
the DVC, EGFP-negative NTS neurons were targeted to increase
the likelihood of recording from a glutamatergic neuron (6).
Once whole-cell configuration was achieved, neurons were
held near their resting membrane potential (RMP) for at least 5
minutes to allow proper equilibration of the cytoplasm and
pipette solution. Acceptable series resistance was considered to
be <25 MW (range = 6.044-24.89 MW; mean = 13.21 ± 0.36 MW)
and was regularly monitored; recordings were discarded if series
resistance or cell capacitance changed by ≥ 20% during
recording. All voltage values were corrected post-hoc for the
liquid junction potential (calculated at -15 mV). Excitatory
postsynaptic currents (EPSCs) were recorded at -85 mV, the
approximate reversal potential for Cl-, to prevent interference by
inhibitory currents. For continuous recordings of EPSCs, 2 min
of activity was analyzed. Input resistance (Rin) was calculated as
the slope of the line that best fit the points produced by 500 ms
negative current injections ranging from -20 pA to 0 pA in 5 pA
increments. Neurons were considered responsive if FGF19
produced a ≥20% change in Rin. Current versus action
potential frequency (I-F) analysis was made in the same group
of neurons that were used to measure Rin by measuring action
potentials resulting from positive current injections ranging from
0 pA to 20 pA in 5 pA increments.
Similar to previous reports of glutamate photoactivation in
the DVC (12, 33, 34), MNI-caged glutamate (250 µM) was added
to recirculating ACSF and uncaged using 30 ms pulses of UV
light (UV filter; Chroma Technology, Rockingham, VT). UV
light, controlled by an automated shutter system (Uniblitz
VMM-D1, Vincent Associates, USA), was directed to the slice
through the 40X water immersion objective. Aperture width was
set to minimum to stimulate a small patch of neurons
(approximately 75 µm diameter stimulation region). When
light was positioned directly over the recorded cell, UV pulses
produced large, fast inward currents in voltage-clamp mode and
significant depolarization in current-clamp mode (typically >200
pA and >20 mV, respectively). To find extant glutamatergic
connections, the objective was systematically moved throughout
the AP or NTS until the UV pulse produced a detectable synaptic
response. Care was taken not to directly photostimulate the
recorded neuron, thus ensuring that any observed response
was due to glutamate stimulation of neurons that projected to
the recorded cell. Recordings consisted of 10 repetitions of: A one
second pre-stimulus period, a 30 ms UV pulse, then a two second
post-stimulus period. Results were reported as a difference in
EPSC frequency during the 500 ms immediately after stimulation
versus that in the 1-second period before stimulation. Successful
glutamate uncaging was defined as a >1 Hz change in frequency.
Mean fold change was obtained by averaging the individual fold-
change values of each neuron.
Statistics and Analysis
Recordings were analyzed using pClamp 10.6 (Axon
Instruments), Minianalysis 6.0.7 (Synaptosoft, Decatur, GA,
USA), SAS 9.4 (SAS Institute, Cary, NC, USA) and Prism 8
(GraphPad Software, San Diego, CA, USA). Within-cell analysis
of multi-event recordings (e.g., EPSCs before and after drug
application) was performed using the 2-sample Kolmogorov-
Smirnov (K-S) test. Grouped analyses were performed using a
paired t-test when one before/after pair was present or repeated
measures generalized linear mixed model with Tukey multiple
comparisons when multiple before/after pairs were present.
Significance was set at p<0.05 for all analyses. Unless otherwise
indicated, data are presented as mean ± SEM.
RESULTS
FGF19 Increases the Excitability Of
Glutamatergic AP and NTS Neurons That
Project to the DMV in Hyperglycemic Mice
Previous reports found that FGF19 increased action potential-
dependent glutamate release in the DMV in hyperglycemic mice
(6). Both the NTS and AP remain intact in the slice preparation,
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express abundant FGF receptors, and project glutamatergic
projections to the DMV (26, 28, 35). Thus, it was determined
that these areas were the most likely source of excitatory input.
To identify the effect of FGF19 on excitatory neurotransmission
from the NTS and AP to the DMV, glutamate photostimulation
was performed in these areas while recording EPSCs in DMV
neurons (Figure 1). Briefly, the effect of glutamate uncaging was
determined by measuring the difference in EPSC frequency
before and after UV light pulses. All recordings were made in
the presence of picrotoxin (100 µM), a GABA receptor type-A
blocker, to prevent any effects caused by stimulating local
GABAergic neurons.
When glutamate photostimulation was performed in the NTS
of control mice, FGF19 failed to alter the mean effect of
glutamate photostimulation in the NTS on EPSC frequency in
the DMV (Figure 1C; ACSF: 5.78 ± 1.05 Hz; FGF19: 5.81 ± 1.38
Hz; n = 7; p=0.409). Since there was no overall effect on the
response to photostimulation in the NTS, and since there was no
effect of FGF19 on sEPSC frequency in DMV neurons from
control mice previously (6), no further uncaging experiments
were performed in this group. When glutamate photoactivation
was performed in the NTS of T1DM mice, FGF19 significantly
increased the mean effect of glutamate photostimulation in the
NTS on EPSC frequency in the DMV (Figure 1F; ACSF: 5.18 ±
1.02 Hz; FGF19: 7.52 ± 0.91 Hz; n = 10; p=0.016). This
represented an average 1.84-fold increase in the response.
Similarly, when glutamate photolysis was performed in the AP
in T1DM mice, FGF19 significantly increased the mean effect of
glutamate photostimulation (Figure 1I; ACSF: 3.62 ± 0.82 Hz;
FGF19: 8.16 ± 1.21 Hz; n = 5; p=0.004). This represented an
average 2.6-fold increase in the response. Together, these data
suggest that FGF19 increases the excitability of glutamatergic
neurons in the AP and NTS that project to the DMV in
hyperglycemic mice.
FGF19 Produces Mixed Effects on Intrinsic
Excitability of NTS Neurons
To determine the effects of FGF19 on intrinsic excitability of NTS
neurons, resting membrane potential (RMP) and input
resistance (Rin) were measured in current-clamp mode
(Figures 2A–F). Recordings were performed in control and





FIGURE 1 | FGF19 increases the excitability of glutamatergic AP and NTS neurons that project to the DMV in hyperglycemic mice. (A) Diagram showing a typical
stimulation and recording location for cells in (B, C) (normoglycemic control mice). (B) Representative voltage clamp recordings of evoked EPSCs for the NTS to
DMV circuit in control mice. (C) Evoked EPSC response in control mice before and after addition of FGF19 (230 pM; n = 7; *p > 0.05). (D) Diagram showing a typical
stimulation and recording location for cells in (E, F) (hyperglycemic mice). (E) Representative voltage clamp recordings of evoked EPSCs for the NTS to DMV circuit
in hyperglycemic, type 1 diabetic mice (T1DM). (F) Evoked EPSC response in this group before and after addition of FGF19 (n = 10; *p < 0.05). (G) Diagram showing
a typical stimulation and recording location for cells in (H, I) (hyperglycemic mice). (H) Representative voltage clamp recordings of evoked EPSCs for the AP to DMV
circuit in T1DM mice. (I) Evoked EPSC response in this group before and after addition of FGF19 (n = 5; **p < 0.01). In representative traces, blue rectangle
indicates stimulation time and duration. Arrows point to an expanded trace showing 500 ms before and after stimulation. All cells recorded at -85 mV. In (A, D, G),
the blue circle represents a typical photostimulation region. The actual area of photostimulation was smaller in diameter (~75 µm) than the circle pictured and stimuli
were applied to multiple areas in the indicated nucleus. Paired t-test used for all analyses. All recordings performed in the presence of MNI-caged glutamate (250
µM) and picrotoxin (100 µM).
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the effect of FGF19 in these neurons as suggested by previous
findings (6). A neuron that displayed a >20% change in Rin or >2
mV change in RMP was considered responsive to FGF19. In
neurons from control mice, FGF19 modestly but significantly
decreased mean Rin (Figure 2C; ACSF: 1.38 ± 0.07 GW; FGF19:
1.21 ± 0.07 GW; n = 60; p=0.0011). In this group, FGF19
produced a change in Rin in approximately 50% of neurons
with a trend towards lower Rin (8 increased; 21 decreased; 31 no
change). FGF19 did not alter mean RMP in NTS neurons from
control mice (Figure 2D; ACSF: -63 ± 1.22 mV; FGF19; -63.6 ±
1.29 mV; n = 60; p=0.2279), but individual neurons responded
with a change in RMP in similar proportions to those observed
with Rin (8 increased; 16 decreased; 36 no change). In neurons
from T1DM mice, FGF19 produced a small but significant
decrease in mean Rin (Figure 2C; ACSF: 1.51 ± 0.11 GW;
FGF19: 1.33 ± 0.14 GW; n = 26; p=0.0202). In this group,
FGF19 altered Rin in 50% of neurons with a predominately
inhibitory effect (2 increased, 11 decreased, 13 no change).
FGF19 also hyperpolarized the mean RMP in this group
(Figure 2D; ACSF: -59.5 ± 1.37 mV; FGF19: -62.3 ± 1.72 mV;
n = 26; p=0.0001). Similarly to Rin, FGF19 altered RMP in
approximately half of neurons (0 increased, 12 decreased, 14
no change). Neither Rin nor RMP differed between control and
T1DM groups prior to FGF19 application. Moreover,
proportions of neurons that responded to FGF19 did not differ
between groups for both Rin (Control; Responsive: 29; Non-
responsive: 31; T1DM; Responsive: 13, Non-responsive: 13;
p>0.99; Fisher’s exact test) and RMP (Control; Responsive: 24;
Non-responsive: 36; T1DM; Responsive: 12; Non-responsive: 14;
p = 0.63; Fisher’s exact test). To identify the effects of FGF19 on
action potential responsiveness in the NTS, positive current step
recordings were performed in the same neurons to produce
evoked action potentials (Figures 2G–J). In neurons from
control mice, FGF19 decreased mean evoked action potential
frequency at the 10 pA current step (Figure 2I; n = 60;
p=0.0253). In neurons from T1DM mice, FGF19 decreased
mean evoked action potential frequency at the 10, 15, and 20
pA current steps (Figure 2J; n = 26; 10pA, p = 0.0314; 15 pA, p =
0.0135; 20 pA, p = 0.0408). These data suggest that FGF19
produces mixed effects that trend toward inhibition in NTS
neurons that responded. Importantly, these effects did not
differ between groups.
FGF19 Increases sEPSC Frequency in NTS
Neurons From Hyperglycemic Mice
Because FGF19’s effects on intrinsic excitability were inconsistent
with its effects on spontaneous EPSC frequency reported
previously (6), and since FGF19 consistently increased EPSCs
in the DMV after glutamate photolysis in either the NTS or AP,
excitatory neurotransmission to NTS neurons was measured. To
assess this, NTS neurons were voltage-clamped at -85 mV to
record spontaneous EPSCs (sEPSC) before and after bath
application of FGF19 (Figure 3). In neurons from control
mice, FGF19 did not significantly alter mean sEPSC frequency
(Figure 3G; ACSF: 3.02 ± 0.51 Hz; FGF19: 2.89 ± 0.47 Hz; n = 14;
p=0.5940). In this group, FGF19 altered sEPSC frequency in 7
out of 14 neurons (2 increased; 5 decreased; p < 0.02, within
recording K-S test). FGF19 also failed to produce effects on mean
sEPSC amplitude in this group (Figure 3H; ACSF: 14.4 ± 1.04
pA; FGF19: 14.0 ± 1.07 pA; n = 14; p=0.5813). In neurons from
T1DM mice however, FGF19 significantly increased mean
sEPSC frequency (Figure 3G; ACSF: 3.60 ± 0.43 Hz; FGF19:
4.62 ± 0.57 Hz; n = 13; p=0.0004). In this group, FGF19 altered
sEPSC frequency in all neurons, with a predominately excitatory
effect (11 increased; 2 decreased; p<0.02, K-S test). FGF19 subtly
altered mean sEPSC amplitude in this group (Figure 3H; ACSF:
17.7 ± 1.31 pA; FGF19: 15.3 ± 1.09 pA; n = 13; p=0.001). Neither
sEPSC frequency nor sEPSC amplitude differed between the
control and T1DM groups prior to FGF19 application.
Together, these data show that FGF19 increases spontaneous
excitatory synaptic input to the NTS in T1DM but not
normoglycemic mice, similar to our previous findings in the
DMV (6).
FGF19 Does Not Alter mEPSC Frequency
in NTS Neurons From Hyperglycemic Mice
FGF19 increased mean spontaneous excitatory neurotransmission
in neurons from T1DM, but not normoglycemic mice, so further
experiments were performed to understand the nature of this
effect in T1DM mice only. To determine whether the effect on
sEPSCs was due to actions at the soma or terminal of the
presynaptic neuron, action potential independent, “miniature”
excitatory postsynaptic currents (mEPSCs) were recorded
(Figure 4). NTS neurons from T1DM mice were recorded
similarly to the sEPSC recordings above with the addition of
TTX (2 µM) to prevent action potentials. Unlike for sEPSCs,
FGF19 failed to alter mean mEPSC frequency in DMV neurons
from T1DM mice (Figure 4C; ACSF: 2.60 ± 0.47 Hz; FGF19:
2.26 ± 0.60 Hz; n = 9; p=0.210). FGF19 also did not alter mean
mEPSC amplitude (Figure 4D; ACSF: 26.0 ± 4.34 pA; FGF19:
23.1 ± 3.64 pA; n = 9; p=0.071). These data, taken with the sEPSC
results above suggest that FGF19 consistently produced a net
increase in synaptic excitation of NTS neurons from T1DMmice.
Because this increase in sEPSC is abrogated in the presence of
TTX, FGF19 likely increases the activity of intact glutamatergic
neurons afferent to the NTS.
FGF19 Increases the Excitability of
Glutamatergic AP Neurons That Project
to the NTS in Hyperglycemic Mice
Since FGF19 was found to increase the effect of glutamate
photostimulation of AP neurons and since the AP has
glutamatergic projections to both the NTS and DMV (35), it
was hypothesized that the AP was also a likely source of local
excitatory input to the NTS. To identify the effects of FGF19 on
glutamatergic neurotransmission from the AP to the NTS,
glutamate uncaging was performed to increase activity of AP
neurons while recording from neurons in the NTS (Figure 5).
Because FGF19 was found to increase sEPSC frequency in NTS
neurons from T1DM mice only, further glutamate uncaging
experiments were restricted to this group of mice. When
glutamate photostimulation was performed in the AP, FGF19
Wean and Smith FGF19 Effects on DVC Circuits
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significantly increased the mean effect of uncaging on EPSC
frequency in the NTS (Figure 5C; ACSF: 4.34 ± 1.10 Hz; FGF19:
7.12 ± 0.98 Hz; n = 5; p=0.037). The averaged fold-change of all
cells in this group was 1.96. Together, these data suggest that
FGF19 increases the excitability of glutamatergic AP neurons
that project to the NTS in hyperglycemic mice.
DISCUSSION
These results indicate that FGF19 increases glutamatergic
transmission at multiple points in DVC circuitry in
hyperglycemic, but not normoglycemic mice, which implies a
mechanistic understanding of FGF19 activity in the hindbrain.
We found previously that FGF19 decreased blood glucose in
hyperglycemic mice through actions in the dorsal hindbrain, and
this effect was abrogated by co-administration of a peripheral
muscarinic receptor blocker (6), suggesting a parasympathetic
mechanism. Similar to the current findings, we also found that
FGF19 altered the excitability of DMV neurons in a complex
manner that was heavily influenced by hyperglycemic state.
These results suggested that FGF19 functioned in the DVC
through a relatively restricted mechanism (i.e., that FGF19
modified the activity of central vago-vagal reflexes, resulting in
altered parasympathetic output). The current findings expand
upon what was established previously by identifying multiple
local, excitatory synaptic circuits within the DVC that are
positively modulated by FGF19 to increase glutamate release in
the DMV. These results are especially intriguing considering
that, while the DMV is typically associated with autonomic
regulation, the NTS and AP show extensive interconnectivity
with several other brain regions involved in regulating
metabolism (8, 35, 36, 44–46). This suggests that FGF19 in the
hindbrain may regulate metabolism through multiple
mechanisms in addition to autonomic changes, which is
consistent with the diverse effects produced by ICV FGF19
reported previously (2–4, 47).
Previous data showed that the effect of FGF19 on EPSC
frequency in the DMV was blocked by TTX, suggesting a
neuronal source that remained intact within slice preparation.
Although the source was unknown, it was hypothesized to be the
NTS, since it is a primary source of synaptic input to the DMV
and expresses the receptors/co-receptor required to respond to





FIGURE 2 | FGF19 produces mixed effects on intrinsic excitability of NTS neurons. Representative current step recordings in current clamp mode from (A) control
and (B) T1DM mice. (C) FGF19 significantly decreased mean input resistance in both control (n = 60; **p < 0.01) and T1DM mice (n = 26; *p < 0.05). (D) FGF19 did
not alter mean resting membrane potential in control mice (n = 60; p > 0.05) but significantly hyperpolarized mean RMP in T1DM mice (n = 26; ***p < 0.001). (E)
Averaged current-voltage relationship in seen control mice (n = 60). (F) Averaged current-voltage relationship seen in T1DM mice (n = 26). Representative traces
showing action potential response to positive current injections in control (G) and T1DM mice (H). (I) Averaged action potential frequency response to positive
current injections in control mice (n = 60; p < 0.05). (J) Averaged action potential frequency response to positive current injections in T1DM mice (n = 26; p < 0.05).
For all panels, * indicates p < 0.05; ** indicates p < 0.01, *** indicates p < 0.001. Repeated measures generalized linear mixed model analysis used for all analyses.
No pharmacological blockers were included for these experiments.
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suggest the intriguing hypothesis that the AP may also
participate in the response of DMV neurons to FGF19. Indeed,
the AP displays significantly higher expression of multiple
FGFRs and ß-klotho than the NTS and shows some of the
highest expression levels of any brain area (26). Thus, neurons
in the NTS and AP were tested regarding the effects of FGF19 on
their glutamatergic connections to the DMV.
The glutamate photolysis experiments performed here
demonstrated that FGF19 increases the excitatory synaptic
input to the DMV arising from both AP and NTS neurons.
The involvement of the NTS was predicted, since the excitatory
glutamatergic NTS to DMV circuit has been well-characterized
(9, 11, 12, 50). However, there is little known about the role of the
AP in local vagal circuitry. Interestingly, there is evidence to
suggest that the AP may be an unappreciated participant in the
canonical vago-vagal reflex circuit. Several early tracing studies
(51–54), later confirmed with viral and genetic techniques (35,
55, 56), found that the AP receives vagal sensory input and
projects glutamatergic output toward the NTS and DMV. This
suggests that the AP may serve as a vagal sensory integration
center, in a similar capacity as the NTS. Despite this,
electrophysiological studies exploring the role that the AP
plays in regulating local DVC circuitry have been few and
more work is warranted to understand this connection (57–60).
The current findings confirm that AP neurons can modulate
DMV activity via glutamatergic synaptic connections and that
FGF19 increases the activity of this input. This does not
necessarily imply the existence of a monosynaptic connection,
since it is possible that the AP regulates DMV activity through
intermediary NTS neurons. However, considering the
widespread glutamatergic innervation from the AP throughout
the DVC and the extensive dendritic fields of DMV neurons, it is
likely that the AP communicates to the DMV both mono- and
polysynaptically (35, 61). A priori, in light of the AP’s traditional
role as the principal emetic center in the brain, the existence of a
monosynaptic connection from AP to DMV seems logical. This
would allow for rapid control of gastric motility and stomach
muscle contraction in response to noxious stimuli in the blood.
Uncaging glutamate over a neuron causes a transient
membrane depolarization that subsides over a period of ~500
ms. Consequently, an increased response to uncaging, as was
seen here, is presumed to be the result an increase in excitability
in the afferent neuron. Initial uncaging experiments indicated an
increase in glutamatergic NTS neuron excitability in T1DM
mice. To understand this, we first measured the intrinsic
membrane properties of these neurons in both control and
T1DM mice. The mouse model used here expresses EGFP in
GABAergic neurons, so to increase the likelihood of obtaining
responses from glutamatergic neurons, only EGFP-negative
neurons were targeted for recording, though this does not
imply that all neurons were glutamatergic. FGF19 produced a
mixed effect on intrinsic membrane properties in these neurons,
A
B D
E F G H
C
FIGURE 3 | FGF19 increases sEPSC frequency in NTS neurons from hyperglycemic mice. (A, B) representative voltage clamp recordings of sEPSCs in NTS
neurons from control mice. (C, D) Representative voltage clamp recordings of sEPSCs in NTS neurons from T1DM mice. (E) Cumulative fraction plot for the traces
from (A, B). (F) Cumulative fraction plot for the traces from (C, D). (G) FGF19 does not alter sEPSC frequency in control mice (n = 14; p > 0.05) but significantly
increases sEPSC frequency in T1DM mice (n = 13; ***p < 0.001). (H) FGF19 does not alter sEPSC amplitude in control mice (n= 14; p > 0.05) and slightly decreases
sEPSC ampltide in T1DM mice (n = 13; **p < 0.01). Arrow indicates 2 s expanded portions indicated by the black bar above the trace. All cells recorded at -85 mV.
Repeated measures generalized linear mixed model analysis used for all analyses. No pharmacological blockers were applied for these experiments.
Wean and Smith FGF19 Effects on DVC Circuits
Frontiers in Endocrinology | www.frontiersin.org November 2021 | Volume 12 | Article 7653597
which did not appear to be dependent on hyperglycemic state. In
both control and T1DM groups, FGF19 failed to alter Rin and
RMP in approximately half of NTS neurons. In the neurons that
did respond, FGF19 tended to produce relatively subtle
inhibitory effects, although a small proportion of neurons were
excited by FGF19. Similarly, FGF19 produced a predominately
inhibitory effect on evoked action potential firing in response to
positive current injections. These responses were mainly similar
to our previous results in the DMV, which noted a modest
inhibitory effect of FGF19 on intrinsic properties of DMV
neurons in both control and T1DM groups, suggesting that the
peptide may interact with a common intracellular pathway
downstream from the FGFR that is not modified by
hyperglycemia (6).
The effects of FGF19 on NTS intrinsic excitability run
contrary to the excitation that was predicted by glutamate
uncaging. Although it is possible that the small proportion of
NTS neurons that were excited by FGF19 was responsible for the
increase in evoked EPSCs in T1DMmice, further experiments on
synaptic excitability were warranted. FGF19 significantly
increased sEPSC frequency in most NTS neurons from T1DM
mice, with no overall effect in control mice. This is consistent
with the findings from Figure 1 and is likely a key driver of the
FGF19-induced increase in NTS to DMV excitatory
transmission. Intriguingly, and in contrast to several other
metabolic hormones, this effect was abolished with the
addition of TTX, suggesting the involvement of intact
upstream neurons (21, 62). The small decrease in mean sEPSC
amplitude is likely due to an increase in frequency of lower
amplitude events and not a postsynaptic mechanism, since this
effect was not retained with the addition of TTX. Since FGF19
was found to increase the activity of the AP to DMV
glutamatergic connection, the effect of AP input to the NTS
was tested. As hypothesized, glutamate release in the NTS that
was due to activity of AP neurons was increased by FGF19.
Together, these results suggest that FGF19 increases
glutamatergic neurotransmission at multiple points in the




FIGURE 4 | FGF19 does not alter mEPSC frequency in NTS neurons from hyperglycemic mice. (A, B) representative voltage clamp recordings in NTS neurons from
T1DM mice in the presence of TTX (2 µM). (C) FGF19 failed to alter mean mEPSC frequency (n = 9; p > 0.05). (D) FGF19 failed to alter mean mEPSC amplitude (n =
9; p > 0.05). All cells recorded at -85 mV. Paired t-test used for all analyses. All recordings performed in TTX (2 µM).
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decreases blood glucose concentration in T1DM but not control
mice (6, 63, 64). This suggests that the effects on blood glucose
are likely to be determined by neurophysiological differences
between control and T1DM groups. Although FGF19 produced
intrinsic inhibition in some NTS neurons, this effect was broadly
similar between both animal groups and was relatively modest.
Moreover, the effects on intrinsic excitability of NTS neurons do
not appear to be consequential regarding their net excitatory
influence on DMV neurons in T1DM mice. Rather, the more
substantial effects of FGF19 on excitatory synaptic activity in
T1DM mice play a greater role in the peptide’s effect on vagal
motor output. The effects on intrinsic properties of NTS neurons
observed here are also consistent with our prior results showing
that FGF19 produced a small decrease in sEPSC frequency in
some DMV neurons from control mice (6).
In addition to neuronal input, the DVC regulates metabolism
in response to humoral signals. The AP and NTS lack a fully
functional blood-brain barrier due to the presence of local
fenestrated capillaries, which could allow the diffusion of
humoral components into the DVC that might typically be
excluded (19). Additionally, NTS and DMV neurons have wide
dendritic fields (61, 65) that can extend to the AP border. As
such, it is likely that neurons in all three DVC nuclei can sense
and respond to humoral signals. FGF19 crosses the blood-brain
barrier, albeit slowly, but it is unknown whether its entry into the
brain is enhanced in areas that contain fenestrated capillaries
(66). Neurons in the DVC have been shown to respond to many
primary metabolic hormones (21–25, 34, 67). Similar to the
effects of FGF19 described here, leptin, insulin, CCK-8, and
ghrelin modify glutamatergic, but not GABAergic transmission
A
B C
FIGURE 5 | FGF19 increases the excitability of glutamatergic AP neurons that project to the NTS in hyperglycemic mice. (A) Representative voltage clamp
recordings of evoked EPSCs for the AP to NTS circuit in T1DM mice. (B) Diagram showing a typical stimulation and recording regions for cells in (A, C). (C) Evoked
EPSC response in this group before and after addition of FGF19 (n = 5; *p < 0.05). In representative traces, blue rectangle indicates stimulation time and duration.
Arrows point to an expanded trace showing 500 ms before and after stimulation. All cells recorded at -85 mV. Paired t-test used for analysis. All recordings
performed in MNI-caged glutamate (250 µM) and picrotoxin (100 µM).
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in the DVC (21, 22, 34, 62, 68). Despite this, GABAergic
transmission is considered to be a primary determinant of
DMV neuron activity during resting conditions, since blockade
of glutamatergic transmission in this area fails to produce effects
on gastric motility or pancreatic secretion in normoglycemic
mice (9, 11). However, an NMDA receptor antagonist applied
to the NTS attenuated jejunal nutrient sensing-mediated
mechanisms of glucose production (69). Interestingly,
chemogenetic silencing of GABAergic NTS neurons fails to
alter blood glucose concentration in normoglycemic mice,
whereas increasing GABA neuron activity in the dorsal
hindbrain increases blood glucose concentration (15). This
suggests that glucoregulatory DMV neurons may not show the
same GABA-dominant phenotype seen with other functional
DMV subgroups.
The changes in cellular excitability in the DVC seen here are
consistent with the beneficial metabolic effects associated with
ICV administration of FGF19. ICV FGF19 has been shown to
decrease hepatic glucose production (2) and hepatic expression
of G6Pase, a key enzyme required for gluconeogenesis (3). These
effects can be replicated by injection of excitatory
neurotransmitters into the DVC (14) or by activating DMV
neurons as measured by c-fos staining (70). Additionally, a
common hallmark of FGFR activation is induction of
phosphorylated extracellular signal-related kinase (pERK).
Insulin activation of ERK signaling in the DVC is sufficient to
decrease hepatic glucose production, suggesting that FGF19 may
share this mechanism (67). Injection of NMDA in the DVC
lowers hepatic glucose production and this effect was prevented
by a hepatic vagotomy, suggesting that the effect was mediated by
the excitation of DMV neurons (14). Additionally, increasing
synaptic inhibition to the DMV increases blood glucose
concentration (15). Together, these results are consistent with
a model in which increased excitatory input to the DMV
produces a decrease in blood glucose concentration (71).
Accordingly, the effects of FGF19 seen here on DVC circuit
dynamics are likely to produce beneficial effects on blood glucose
levels in diabetic animals.
The effects of FGF19 in the DVC found here may also
modulate metabol ism independent ly of autonomic
mechanisms. Central delivery of FGF19 has been shown to
decrease food intake, which could be explained by alterations
in DVC neuron activity (4, 47). Similar to the effects of insulin on
hepatic glucose production, satiation produced by CCK in the
DVC requires induction of pERK, suggesting that FGF19 may
decrease food intake via a shared mechanism. The NTS and AP
also exhibit significant connections to other nuclei associated
with regulation of ingestive behavior including the lateral
parabrachial nucleus (PBN) (35, 72) and the hypothalamus
(73). The experiments performed here focus on local circuitry
within the DVC. As such, it is not known whether connections to
other nuclei such as the PBN or hypothalamus are altered by
FGF19. However, considering the significant expression of
FGFR/b-Klotho throughout the NTS and AP, it is likely that
FGF19 alters the activity of neurons that project centrally as well
as those that participate in local vago-vagal reflexes (26, 28).
The DVC is a key metabolic regulatory area of the brain.
Although the DVC is typically associated with autonomic
regulation of metabolism, the AP and NTS also serve as a
communication hub between the DVC and several other key
nuclei. Alterations in DVC neuron activity, such as those seen
here, are likely to produce profound effects on multiple aspects of
metabolism. Consistent with our previous work, these results
suggest that FGF19 alters parasympathetic output in T1DM
mice by increasing synaptic excitability of DMV neurons.
Interestingly, our findings demonstrate a role for the AP in the
direct regulation of vago-vagal reflex mechanisms and that this
connection can be modified by a metabolic hormone. Though
not confirmed, it is possible that other metabolic hormones work
similarly in this area. Overall, the electrophysiological effects seen
here are consistent with the beneficial metabolic effects of ICV
FGF19. Although these findings implicate a primarily autonomic
mechanism, FGF19 was also found to significantly alter synaptic
inputs originating from the AP and NTS. This raises the
possibility that FGF19 may interact with the DVC to produce
an array of beneficial metabolic effects through alteration of vagal
parasympathetic output and possibly also through connections
with other important metabolic regulatory nuclei.
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